Eighty-two patients who survived a myocardial infarct were treated continuously with anticoagulants for periods of 3 to 76 months. Another 88 patients whose treatment with anticoagulants was limited to the acute phase of an infarction and who were observed for similar periods acted as a control group. The group treated continuously exhibits a lower mortality rate with fewer recurrences of infarction. Among the factors subjected to statistical analysis and found to influence the ultimate prognosis unfavourably and which therefore serve as indications for long-term anticoagulant therapy, are a severe presenting attack and a history of previous infarction.
ALONG-TERM clinical study was undertaken to determine whether the prognosis of myocardial infarction could be improved by anticoagulant therapy continued indefinitely after recovery from the acute phase of the disease. Since the beneficial effect of anticoagulants in acute arterial thrombosis was thought to be largely prophylactic in the sense that further thrombus formation or the propagation of an existing thrombus may possibly be prevented, it was considered rational to apply this therapy on a long term basis with a view to preventing recurrences of coronary thrombosis and myocardial infarction.
Furthermore, since atheroma is generally accepted as the underlying pathological process responsible for the ultimate precipitation of acute occlusion by thrombosis as well as for progressive coronary artery narrowing, it was considered of fundamental importance that an experimentally produced intra-arterial thrombus, after having undergone organization and endothelialization, presents eventually as a lesion histologically indistinguishable from that of atheroma even to the extent of exFrom the General Hospital, Johannesburg, South Africa. Presented at the Second World Congress of Cardiology, September 12-17, 1954 , in Washington, D.C. 338 hibiting the characteristic fatty changes, calcification and ulceration.'-4 Based on the concept that atheroma may result from intraarterial mural thrombus formation rather than, as is currently thought, from a lesion of obscure metabolic origin arising subendothelially in the vessel wall, the long continued administration of anticoagulants would appear to be rational therapy for the prevention of progressive coronary artery disease. The first long-term anticoagulant regime for myocardial infarction to be instituted in this series was commenced in November 1946 in a 60 year old man with a history of three previous attacks. The treatment was carried out continuously until his death from a recurrent infarction in September 1949. Whemi it was realized that the continuous long-term use of anticoagulants was a practical and rela- iively safe procedure with prothrombin levels estimated at intervals of one or two weeks, this regimen was gradually adopted for the treatment of more patients with myocardial infarction.
As the aim of this clinical study was to assess specifically the possible value of anticoagulant therapy given continuously on a long-term basis, it was considered advisable that a control series of patients with myocardial infarction should be observed parallel with the treated SUZMAN, RUSKIN AND GODRDBE3RG series and moreover that this control group should be comprised only of patients who had received anticoagulant therapy for a period of time limited to the acute phase of the disease. In this way a comparison could be made between the effects of short-term and long-term anticoagulant therapy rather than between anticoagulant therapy and no such treatment. Furthermore, any difference noted in the prognosis of the patients receiving long-term anticoagulant therapy could not then be interpreted as a remote effect of the anticoagulants given during the acute phase of the disease. Consequently, patients with myocardial infarction who did not receive anticoagulant therapy during the acute phase were excluded from the control group.
MATERIALS AND M\IETHODS
Two hundred and eight patients, having received anticoagulant therapy during the acute phase of an attack of mvocardial infarction, who survived for three months or more, were followed until their death or until the end of the period of the authors' study (Sept. 1,1953) .
Of the 208 patients, 120 received anticoagulants continuously for three months or longer, but 38 of these discontinued the treatment after periods ranging from 3 to 30 months or were treated intermittently and are therefore excluded from this comparative study. Thus, 82 patients have received anticoagulant therapy continuously for periods ranging from 3 to 76 months, and are designated the "long-term group". Eighty-eight patients who received anticoagulant therapy only for a period of time limited to the acute phase of the presenting attack or of subsequent attacks of mvocardial infarction and who were observed for periods ranging from 3 to 72 months serve as controls and are designated the "short-term group".
Selections of Patients for Long-Term Therapy
The patients were drawn from unselected hospital admissions and private practice and the two groups run parallel in time over a period of up to 76 months. After the patients had recovered from the acute phase of the disease, the question of whether or not to continue with anticoagulant therapy for an indefinite period was raised with the patient and the family doctor. The reasons for advocating this form of treatment were fully explained in simple language and the implications of embarking on such a regime were pointed out. The need for regular attendance at the clinic and the laboratory and the inherent dangers of anticoagulant therapy were stressed. Persuasion was not resorted to and the final decision was left to the patient.
In the patients who had suffered previous episodes of myocardial infarction and in those whose presenting attacks were severe, there was a tendency to accept this regimen more readily than in the patients experiencing their first attack, particularly if it happened not to be severe. In those for whom adequate laboratory facilities were not available, such as patients living in the country districts, it was explained that the regimen could not be contemplated unless the patient was prepared to make regular visits to a laboratory. Those who declined or were unable to undertake the continuous treatment constituted the group which serves as a control.
A number of patients commenced the treatment but discontinued after varving periods for different reasons. Reports in the lay press and unsolicited advice from friends, stressing the danger of hemorrhage with the use of Dicumarol, influenced a further group. Some patients found the need for regular attendance at the laboratory tiresome or inconvenient and in others the deciding factor w-as the onset of hemorrhagic complications, which even when mild sometimes served as an excuse for terminating the anticoagulant regimen.
Anticoagulant Medication
During the acute phase of mvocardial infarction heparin w-as used initially in the majority of patients for periods ranging from one day to three weeks, the average duration being five to seven (lays, in the dosage which maintained the blood (lotting time at approximately twice the normal. A day or two before discontinuing the heparin, an orally effective anticoagulant was commenced and discontinued after periods ranging from three weeks to three months in the patients of the short-term group, but continued indefinitely in those comprising the longterm group.
Dicumarol was the oral anticoagulant most commonlv used. Tromexan was given a trial in several cases but control was found to be difficult. Recently phenylindandione has been used extensively and Cumopy-ran in a few patients. The required dosage of Dicumarol and phenylindandione has been found to variy widely in the same and different patients. The weekly maintenance dose of Dicumarol ranged between 150 and 1,100 mg., and of phenylindandione between 125 and 700 mg. with an average in the majority of patients for both drugs of 350 to 450 mg.
Control of Long-Term Anticoagulant Therapy
Prothrombin control was maintained in all patients. After a satisfactory level had been obtained, the test was carried out at weekly or two-weekly intervals, while in some of the patients, in whom the prothrombin level remained constant over many months, the intervals were increased to three or even four weeks. When wide fluctuations occurred, more frequent determinations were carried out until a steady level had again been restored. The optimum therapeutic level aimed at was a prothrombin time of twice the normal and was expressed as a percentage, the prothrombin index (P.I.).
The prothrombin level was estimated by the Quick one-stage method or modifications thereof, in the maj ority of cases, but recently a simplified bed-side method using capillary blood, as described by Stein and AWallace,5 has been adopted for patients attending the clinic and found to be satisfactory. A series of parallel determinations using this simplified capillary method and the standard technique were found to show a good correlation.
The optimum therapeutic iange was arbitrarily fixed at a prothrombin index of 40 to 60 per cent. 1. It will be seen that in the long-term group, 19 patients had previous angina alone and 39 had no previous coronary artery disease, whereas in the short-term group 12 patients had previous angina alone and 59 had no previous coronary artery disease. The difference between the two groups in respect of the incidence of previous angina alone, that is, without infarction, shows an excess in favor of the long-term group, but the difference is not statistically significant. (X' = 3.55; 0.10 > p > 0.05). Previous myocardial infarction was found to have occurred in 24 patients in the longterm group and in 17 in the short-term group. The difference, whether estimated in relation to the total number of patients in each group (x2 = 1.78; 0.30 > p > 0.20) or to the number of patients without previous coronary artery disease (x2 = 3.39; 0.10 > p > 0.05), is found not to be statistically significant. However, when the total incidence of previous coronary artery disease in the two groups is compared, namely 43 patients in the long term-group (52.4 per cent) and 29 in the short-term group (33.0 per cent), the difference is found to be statistically significant (XE = 5.93; 0.02 > p > 0.01).
This difference would appear to indicate that a previous history of coronary artery disease could have influenced the decision whether or not to embark on a continuous long-term anticoagulant regime and also must be taken into account in the assessment of the subsequent prognosis.
Degree of Severity of Presenting Attack of
Myocardial Infarction The patients in both groups are separated into those whose presenting attack was considered to have been uncomplicated, designated "mild" in this communication, on the one hand or complicated, designated "severe", on the other. The assessment of the degree of severity is based on accepted clinical criteria as observed during the course of the acute phase of the disease or in retrospect after recovery, rather than, at the time of the onset of the attack as is advocated by some workers in this field.6' The mild cases exhibited no shock and little or no fall in blood pressure. Pain, which if severe, was only of short duration and readily controlled by medication. Arrhythmias, other than occasional extrasystoles, were absent; there was no gallop rhythm, cardiac failure, cardiac enlargement or thromboembolic complication. These patients were not clinically ill and often felt none the worse for their coronary episode. Their recovery was rapid and residual symptoms such as tachycardia, breathlessness and weakness were absent. At first an attempt was made to subdivide all patients who were not considered to have had a mild attack into "moderate" and "marked," but difficulties were encountered in making a sharp distinction between these categories, so that all of these patients have been combined in one group designated "severe."
The diagnosis was confirmed in all cases by electrocardiography and in the majority of instances 12-lead tracings were obtained. The clinical assessment of the degree of severity could frequently be confirmed by the extent of the electrocardiographic changes. Table 4 shows the numbers of patients in the long-and short-term groups whose presenting attacks were mild or severe. It 3 and 76 months, and is set out in table 5 and depicted in figure 2. As will be seen in the long-term group, a somewhat greater number of patients were observed for less than one year and fewer for four years or more. These differences are found not to be statistically significant (X2 = 2.55; 0.20 > p > 0.10). Table 5 and figure 2 also show the mortality at varying periods of observation. It will be seen that all the deaths in the long-term group and the majority in the short-term group occurred before the end of the fourth year of observation. The total number of deaths in the long-term group was six (7.3 per cent) and in the short-term group 29 (33 per cent). This marked difference in mortality between the two groups is statistically highly significant (XE = 15.54; p = 0.001).
When a comparison is made (table 6 and fig. 3 ) of the severe cases of myocardial infarction in the long-and short-term groups by Of the total number of 43 patients considered to have had a mild attack only one died and this occurred in the group not receiving continuous anticoagulant therapy. The difference in the mortality of the patients with mild and severe attacks of infarction is striking. The comparative incidence of subsequent complications will be dealt with later.
Age and Sex in the Fatal Cases (table 7) Since age and sex are considered to be factors influencing the prognosis of myocardial infarction their effect on the mortality was statistically estimated. No significant differences were noted in the mortality in relation to age (X2 = 0.13; 0.95 > p > 0.90). In the series as a whole or in a comparison between the long-and short-term groups, sex was not a factor influencing the subsequent mortality (XE = 1. 14; 0.30 > p > 0.20). 20 months after the presenting attack of myocardial infarction.
In the long-term group, subsequent complications other than angina occurred in a total of 27 patients (32.9 per cent) of whom six (22.2 per ceit) died, whereas in the shortterm group 40 (45.4 per cent) patients had suffered subsequent complications other than angina of whom 29 (72.3 per cent) died. Although there is a greater tendency for these complications to have occurred in the patients of the short-term group, the difference is not significant (X2 = 2.83; 0.10 > p > 0.05). The overall difference in the mortality resulting from these complications, however, is very markedly in favor of the patients receiving long term anticoagulant therapy (X2 = 13.54; p < 0.01).
The Incidence of Angina Pectoris Subsequent to the Presenting Attack of Myocardial Infarction. Following the presenting attack of myocardial infarction, the incidence of angina was approximately the same in the two groups, 41 of the 82 long-term and 39 of the 88 short-term However, when a comparison is made of the relation of previous infarction to subsequent mortality in the long-and short-term groups, it is found that of the 82 patients in the longterm group, 24 had experienced previous myocardial infarction prior to the presenting attack and of these, three (12.5 per cent) died, whereas the remaining 58 patients gave no history of previous infarction, and of these only two (3.4 per cent) died. Of the 88 patients in the short-term group, 17 had experienced previous infarction, and of these 10 (58.8 per cent) died, whereas of the 71 with no history of previous infarction, 17 (29.9 per cent) died. These results show that whether or not the patients receive continuous anticoagulant therapy the subsequent mortality is significantly greater in those who have suffered previous attacks of myocardial infarction (x2 = 4.91; 0.05 > p > 0.02). However, the numbers of fatalities are far less in those receiving continuous anticoagulant therapy (x2 = 7.84; p < 0.01). In fact, from these results it appears that a fatal outcome was no more likely to occur in the patients with a necessary to test whether the relative incidence of previous angina in the two groups may have been a factor in determining the differences observed in the subsequent mortality. Table  13 shows the incidence of previous angina in relation to subsequent deaths of cardiac origin in 129 patients who had not suffe previous myocardial infarction. 1 patients had experienced previous whom three subsequently died (9.7 and 98 patients had had no angin these 16 subsequently died (16.3 (x2 = 0.38; 0.70 > p > 0.50). Tab shows that in the long-term group of 5 w ho had not suffered from previous i 19 had experienced previous angin these none died, whereas 39 had angina, and of these two died (5.1
In the short-term group, 71 pat had no previous infarction and of the experienced previous angina, with t sequent deaths (23 per cent) while 5! no angina with 14 subsequent dea per cent). As the mortality rates for as a whole and for each group sepa not differ materially, it is apparent presence or absence of previous angii influence the prognosis subsequer attack of myocardial infarction.
In a comparison of the subsequent in relation to the incidence of previo in the long-and short-term groups, parent that a greater number of fat curred in the patients not receiving c anticoagulant therapy. The diffe respect of the patients without coronary artery disease is statisti nificant (X2 = 4.53; 0.03 > p > in regard to those with previous ai numbers are too small for accurate tion, although the tendency is in the patients receiving anticoagulant 16 per cent died, but autopsy seldom showed fresh traismural infarction. In 54 per cent of the cases, the treatment was continuous. These authors concluded that the use of long-term anticoagulants probably prevented recurrent infarction and prolonged life in many patients, judging by comparison with a control group of 500 patients.
Although the general consensus of opinion concerning the value of this therapeutic regime is favorable, it must be emphasized that in none of the reported series has due consideration been given to the previous history of coronary artery disease or to the degree of severity of the presenting attack of infarction. Furthermore, in the majority of reports the period of observation has been relatively short and a comparable control series of cases observed parallel in time has not been studied.
The results of our series indicate that in mild or uncomplicated cases, whether under treatment or not, the ultimate outlook is favorable, in sharp contrast to the substantial mortality rate found in severe or complicated cases.
It is obvious, therefore, that in an evaluation of the natural history of this disease or of any therapeutic regimen, due consideration must be given to the degree of severity of the presenting attack and thus the average survival times hitherto reported for several series of patients must be reconsidered in this light. In a recently reported series of patients who recovered from the acute phase of their first infarct, the average survival time was as long as eight years, but this figure is given irrespective of the degree of severity of the attack. In view of the wide variation in survival time for patients who have recovered from acute myocardial infarction, the prophylactic value of anticoagulant therapy can only be determined by a study of a substantial number of patients followed long enough to bear comparison with the observed survival times in this disease.
In the present study a highly significant difference has been noted in a comparison of those receiving and those not receiving anticoagulants in respect not only of the mortality (7.3 per cent and 33 per cent) but also of the recurrence rate of infarction (8.5 per cent and 27.3 per cent). Despite the fact that the differences in regard to recurrence of infarction and to mortality are statistically significant, these results are presented with reservation. It is realized that because the conditions of management of the patients of the two groups following the presenting attack of myocardial infarction were not exactly similar and therefore not strictly comparable, these differences may not be due entirely to the anticoagulant therapy.
The patients receiving long-term therapy attended the clinic or laboratory at regular intervals for prothromnbin tests. ITnder close medical supervision, signs or impending complications were more likely to have been detected in time, ensuring the early institution of appropriate treatment; furthermore, these patients would have had the benefit of advice about their mode of living and any problems arising in their life situation. Sensing an element of protection and security, in the belief that under this medication thrombosis was less likely to occur, as well as the reassurance gained by constant medical supervision may have been factors in allaying the apprehension and fear for the future which so often troubles patients who have experienced one or more attacks of coronary thrombosis. The patients receiving continuous anticoagulant therapy often displayed much interest in the treatment and in their state of health, and it has been argued that this undue concern may act deleteriously by disturbing the patient's peace of mind, particularly when wide fluctuations of the prothrombin level are encountered. We have observed, however, that this is the exception and that by and large these patients are not unduly disturbed but tend rather to display optimism and a sense of security while under this regimen. There are observers3-41 who emphasize the importance of the role that stressful emotional factors may play in the pathogenesis of intravascular thrombosis, so that it is not beyond the realm of possibility that constant reassurance may have influenced the result of this clinical study.
On the other hand, the incidence of complications will have been more accurately recorded in the patients under close medical supervision than in those examined at infrequent intervals. In the latter patients, symptoms and episodes due to recurrences of coronary artery disease may not have been reported by the patient or his family physician or may have escaped recognition and thus will not have been documented. The true incidence of complications in the short-term group is therefore likely to be higher than that recorded. The influence of constant medical supervision and other undetermined circumstances on the ultimate prognosis of myocardial infarction could the better be judged by the "doubleblind placebo" method of clinical trial, but it is unlikely that the observed differences between the two groups can be attributed solely to these factors and it is reasonable to assume that the prolonged use of anticoagulant drugs actually exerted an effect on the circulating blood which prevented intravascular thrombus formation or beneficially influenced the coronary circulation by some mechanism as yet undetermined. That this is possibly true is supported by the recent observations of Sise,42 who reported that when phenylindandione is administered continuously for periods longer than three weeks, it exerts a true anticoagulant effect by increasing the clotting time, as measured not only by the usual method in glassware, but also by noting the clotting time of blood flowing through a needle inserted in a vein obstructed by a tourniquet at a pressure of 50 mm. Hg. The increase in clotting time is attributed by this worker to a reduction of plasma thromboplastin component (PTC) which does not occur until the drug has been given for a period of approximately three weeks but persists for as long as the drug is administered. A similar action of the oral anticoagulants when given to patients for prolonged periods has been noted by Connell43 who finds it sufficient to regulate the dosage of the drug by means of the clotting time of the blood rather than by its prothrombini content. These aspects of the problem have recently been discussed by Hunter,44 who suggested that doses of coumarin anticoagulants much smaller than those in use at present, may prove to be effective by lowering the blood thromboplastin level without the danger of bleeding. The absence of a true anticoagulant effect with Dicumarol when given for short periods may explain why the difference between the treated and untreated cases on a shortterm basis is not as striking as that observed on a long-term basis. The alleged superiority of heparin over the oral anticoagulants in the treatment of acute thrombotic states may possibly also be explained in this way.
SUMMARY AND CONCLUSIONS Two hundred eight patients with myocardial infarction having received anticoagulant therapy during the acute phase and having survived for three months or more, were observed 3 to 76 months until death or the end of the present study (Sept. 1, 1953) . Those patients treated for three months or longer comprise the long-term group while those treated for less than three months comprise the short-term control group. One hundred twenty patients were treated for three months or longer but 38 of them who discontinued treatment after this period of time or who were treated intermittently have been excluded from the comparative study.
The long and short-term groups are compared in respect of mortality, incidence of recurrent infarction, angina and cardiac failure.
Of the 82 patients who constitute the longterm group the mortality rate is 7.3 per cent and there have been seven recurrences of myocardial infarction, whereas of the 88 patients in the short-term group the mortality rate is 33 per cent and there have been 24 recurrences.
Separate comparisons are made of mild and severe cases, and when the former are eliminated, the mortality rate in the long-term group, which now comprises 67 patients, is 9 per cent with seven recurrences of infarction, whereas in the short-term group totalling 60 patients it is 46.7 per cent with 21 recurrences. Of the severe cases with a history of previous infarction, the mortality rate in the long-term group (21 Inter le casos sever con un historia de previe infarcimento, le mortalitate del gruppo a longe durantia, que consisteva de 21 casos, esseva 14,3 pro cento. Le correspondente gruppo a brev e durantia consisteva de 13 casos e rendeva un mortalitate de 66,6 pro ceiito.
Le frequentia de angina post le attacco hospitalisante esseva proximemente le mesme in ambe gruppos, sed alleviamento o melioration de iste condition occurreva in 56 pro cento del casos in le gruppo a longe durantia e in 23 pro cento del casos in le gruppo a breve durantia.
In le curso del studio, dysfunctionamento cardiac occurreva con simile frequentias in ambe gruppos, sed le mortalitate associate con iste complication amontava a 11,8 pro cento in le gruppo a longe durantia, comparate con 57,1 pro cento ill le gruppo a breve durantia. Le presente studio permitte le conclusion que in le caso de patientes in qui le attacco hospitalisante es non solo leve sed etiam le prime e in qui un therapia anticoagulante a breve durantia es utilisate, le prognose es favorabile in relation a subsequente infarctos, dysfunctionamento cardiac, e Inorte sin reguardo a si o non le therapia anticoagulante es continuate indefinitemente. Per contrasto, le patientes profitante le plus probabilemente ab un therapia anticoagulante a longe durantia es le patients in qui le attacco hospitalisante es sever e in qui infarctos myocardiac ha occurrite previemente.
